POP-OUT | CLOSE
 
 
NG,NG-DIMETHYL-L-ARGININE
 
DA2 is found in 9 entries
DA2
  •   Chemical Component Summary   Hide
    Name NG,NG-DIMETHYL-L-ARGININE
    Identifiers N~5~-(N,N-dimethylcarbamimidoyl)-L-ornithine
    (2S)-2-amino-5-[(N,N-dimethylcarbamimidoyl)amino]pentanoic acid
    Synonyms ADMA
    Formula C8 H18 N4 O2
    Molecular Weight 202.25 g/mol
    Type L-peptide linking
    Isomeric SMILES
    InChI
    InChI key YDGMGEXADBMOMJ-LURJTMIESA-N
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB01686   (Stereoisomeric match)
    Name N,N-dimethylarginine
    Groups experimental
    Description Asymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma. It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells. It is closely related to L-arginine, a conditionally-essential amino acid. ADMA interferes with L-arginine in the production of nitric oxide, a key chemical to endothelial and hence cardiovascular health. [Wikipedia]
    Synonyms
    • Asymmetric dimethylarginine
    • Dimethyl-l-arginine
    • Guanidino-n,n-dimethylarginine
    • N(5)-((Dimethylamino)iminomethyl)-L-ornithine
    • N(5)-[(dimethylamino)(imino)methyl]-L-ornithine
    • N(g)-dimethylarginine
    • N(g),N(g)-dimethyl-l-arginine
    • N(g),N(g)-dimethylarginine
    • N(G1),N(G1)-Dimethylarginine
    • N(omega),N(omega)-dimethyl-l-arginine
    • NG,NG-dimethyl-l-arginine
    [more]
    Affected organism Humans and other mammals
    Pharmacology Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is formed by methylation of arginine residues in proteins and released after proteolysis. In this reaction, S-adenosylmethionine is methyldonor and S-adenosylhomocysteine the demethylated product. ADMA and homocysteine are thus biochemically linked. Both plasma homocysteine and ADMA concentrations are increased in patients with renal dysfunction, probably as a result of an impairment in their metabolic, but not urinary, clearance. Hyperhomocysteinemia has been associated with an increased risk of cardiovascular disease in end-stage renal disease, especially in patients without malnutrition and inflammation. Also, plasma ADMA levels have been associated with cardiovascular disease in renal failure patients. Both homocysteine and ADMA are thought to mediate their adverse vascular effects by impairing endothelial, nitric oxide-dependent function resulting in decreased vasodilatation, increased smooth muscle cell proliferation, platelet dysfunction and increased monocyte adhesion.
    Categories Enzyme Inhibitors
    CAS number 102783-24-4
    Targets
    Name Sequence search Pharmacological action Actions
    Nitric oxide synthase, inducible   Search  unknown
    Nitric oxide synthase, endothelial   Search  unknown
     
Ligand Image